Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
PRNewswire - Monday November 23, 1998
Fourteen agents are currently available for adults.
"The availability of Viramune's pediatric formulation represents a great advance for the treatment of HIV-positive children, particularly for those children who are in need of new treatment options," said John L. Sullivan, MD, Professor of Pediatrics, University of Massachusetts Medical School, Worcester. "Some of the currently available agents are very effective, but taste terrible. Getting kids to swallow such drugs is very difficult. Viramune, in comparison, is a pleasant-tasting liquid suspension taken twice daily. We have found that Viramune is easy for children to take and is generally well tolerated."
Viramune is the first agent belonging to the class of drugs called NNRTIs or non-nucleoside reverse transcriptase inhibitors to be approved for use in children. The FDA's decision was based on clinical trials that provide safety, tolerability and pharmacokinetic data supporting Viramune's use in children. To date, more than 360 children have been treated with Viramune in clinical trials. Some have remained on therapy for as long as six years. Viramune has been shown to suppress HIV-1 in adults when used in combination with other antiretrovirals.
In AIDS Clinical Trial Group (ACTG) 180 (BI 1100.882), a multicenter, open-label study, pediatric patients with 6 weeks or less of prior nucleoside therapy were treated with Viramune monotherapy, double therapy with Viramune/AZT (Retrovir«, zidovudine, ZDV), or triple therapy with Viramune/AZT/ddI (Videx«, didanosine) for 28 to 32 weeks. The study findings were published in The New England Journal of Medicine in May 1997. Viramune continues to be studied in ongoing pediatric clinical trials. Preliminary results of ACTG 356, in which patients took a combination of Viramune/AZT/3TC (Epivir«, lamivudine) and ACTG 245, a double-blind, randomized, placebo-controlled trial of 431 children with advanced HIV disease, were presented at the Fifth Conference on Retroviruses and Opportunistic Infections in February 1998.
Viramune is generally well tolerated. The most commonly reported adverse events associated with Viramune use are rash, fever, nausea, headache and abnormal liver function tests. Severe and life-threatening skin reactions and hepatotoxicity, including fatal cases of each, have occurred in patients treated with Viramune. In ACTG 180, rash considered by investigators to be related to Viramune occurred in 16 percent of patients (aged 2 months to 19 years). The most frequently reported adverse events related to Viramune in pediatric patients were similar to those observed in adults, with the exception of granulocytopenia, which was more commonly observed in children. The safety profile of Viramune in neonates has not been established.
Recommended pediatric dosing for Viramune is 4 mg/kg once-daily for 2 weeks, followed by 7 mg/kg twice-daily for children between 2 months and 8 years of age, and 4 mg/kg twice daily for children 8 years and older. The total daily dose should not exceed 400 mg (200 mg twice-daily) for any patient.
Viramune tablets have been available since August 1996 and have been used in more than 50,000 adult patients. Viramune is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on analysis of changes in surrogate end-points. At present, there are no results from controlled clinical trials evaluating the effect of Viramune in combination with other antiretroviral agents on the clinical progression of HIV-1 infection, such as the incidence of opportunistic infections or survival. Viramune should always be administered in combination with at least one additional antiretroviral agent.
Viramune« (nevirapine) is a product of original research done at Boehringer Ingelheim Pharmaceuticals, Inc., a member of the Boehringer Ingelheim group of companies. Viramune is marketed in the United States by Roxane Laboratories, also a member of the Boehringer Ingelheim group of companies. For more information about ACTG 180 or ACTG 356, please call 212-886-3312.
SOURCE: Roxane Laboratories
981123
PR981109
Copyright © 1998 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .